Aidoc Gets FDA 510(k) Clearance for AI-Powered Algorithm for Brain Aneurysms
The new artificial intelligence (AI) algorithm reportedly flags suspected cases of brain aneurysm and facilitates multidisciplinary care.
Could a new artificial intelligence (AI)-enabled advance have an impact in the diagnosis and treatment of brain aneurysms?
The Food and Drug Administration (FDA) has granted 510(k) clearance to Aidoc’s new AI platform for brain aneurysms. In addition to identifying and triaging suspected cases, the algorithm facilitates communication and workflow between radiologists, neurologists and neuroendovascular surgeons, according to the company.
Researchers have estimated that approximately 6.5 million people in the United States have an unruptured brain aneurysm.1 The Brain Aneurysm Foundation has noted that most aneurysms are small, ranging from 1/8 inch to an inch, and ruptured aneurysms are reportedly misdiagnosed or there is a delay in diagnosis in 25 percent of patients who present to health-care providers.1
Elad Walach, the CEO and co-founder of Aidoc, said the new AI-enabled algorithm may help enhance timely diagnosis and care for brain aneurysms.
“In the U.S., there is tragically a brain aneurysm rupture every 18 minutes. It is an acute condition that can quickly turn fatal, so time is of the essence, especially for late-night reading,” maintained Walach. “We’re excited to include this algorithm in our set of neuro solutions, addressing the challenge of providing timely and accurate notifications of brain aneurysm cases.”
Reference
1. Brain Aneurysm Foundation. Available at: https://www.bafound.org/about-brain-aneurysms/brain-aneurysm-basics/brain-aneurysm-statistics-and-facts/#:~:text=An%20estimated%206.5%20million%20people,aneurysm%20ruptures%20every%2018%20minutes. Accessed April 8, 2022.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
